STOCK TITAN

Vivani Medical director’s 99,010-share trade was a buy

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4/A

Rhea-AI Filing Summary

Vivani Medical, Inc. director Aaron Mendelsohn reported acquiring 99,010 common shares on November 18, 2026; a footnote describes a private-sale purchase at $1.01 per share and states gross transaction proceeds of $100,000.10. The transaction row reports indirect holdings of 997,327 shares afterward. A separate footnote lists 1,165,497 shares owned directly and indirectly. The amendment corrects the prior report’s description from a disposition to an acquisition after an administrative error.

Insider Mendelsohn Aaron
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1, F2, F3 99,010 $1.01 $100K
Holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 997,327 shares (Indirect, See footnote); Common Stock — 168,170 shares (Direct)
Footnotes (3)
  1. F1. The reporting person purchased 99,010 shares of the Issuer's common stock in a private sale transaction as disclosed in the Share Purchase Agreement dated as of November 15, 2026 at a price of $1.01 per share, which was the last reported sale price of the Issuers common stock on the Nasdaq on November 13, 2026 (the trading day immediately prior to November 15, 2026). The gross proceeds from this private sale transaction were $100,000.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in the transaction set forth in this footnote.
  2. F2. On November 19, 2026, the reporting person filed a Form 4 which inadvertently included an incorrect transaction code due to an administrative error. This amendment is being filed to reflect the correct transaction code "A" instead of transaction code "D."
  3. F3. The reporting person owns 1,165,497 shares directly and/or indirectly as follows: (i) 168,170 shares of common stock owned by the reporting person, (ii) 150,930 shares in five trusts, each of which has been established for a separate grandchild of the Reporting Person, with each trust owning an aggregate of 30,186 shares of common stock, all trusts with the same terms, over which the Reporting Person has voting and dispositive authority, (iii) 846,397 shares of common stock owned by MFE, LLC over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims pecuniary interest in 20% of MFE, LLC and therefore disclaims 169,279 shares of the 846,397 shares of common stock owned by MFE, LLC, which 169,279 shares are beneficially owned by other members of the limited liability company.
Shares acquired 99,010 shares November 18, 2026 private-sale transaction
Price per share $1.01 November 18, 2026 private-sale transaction
Gross transaction proceeds $100,000.10 Private-sale transaction described in the footnote
Indirect holdings after transaction 997,327 shares Transaction row
Direct and indirect holdings 1,165,497 shares Footnote ownership statement
Direct holdings 168,170 shares Footnote ownership breakdown
private sale transaction financial
"purchased 99,010 shares ... in a private sale transaction"
Share Purchase Agreement financial
"as disclosed in the Share Purchase Agreement"
A share purchase agreement is a written contract that outlines the terms and conditions for buying and selling shares of a company. It specifies details like the price, number of shares, and any special conditions, ensuring both buyer and seller agree on the transaction. For investors, it provides clarity and legal protection, making sure the purchase is clear and enforceable.
voting and dispositive authority regulatory
"over which the Reporting Person has voting and dispositive authority"
pecuniary interest regulatory
"disclaims pecuniary interest in 20% of MFE, LLC"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VANI shares did director Aaron Mendelsohn acquire and at what price?

Aaron Mendelsohn acquired 99,010 shares at $1.01 per share on November 18, 2026, in a private-sale transaction. The transaction row reports indirect holdings of 997,327 shares afterward. No Rule 10b5-1 plan is reported.

What did the VANI Form 4/A correct?

It corrects the prior report’s transaction description from a disposition to an acquisition after an administrative error.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mendelsohn Aaron

(Last)(First)(Middle)
C/O VIVANI MEDICAL, INC.
1350 S. LOOP ROAD

(Street)
ALAMEDA CALIFORNIA 94502

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
11/19/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/18/2026(1)A99,010(1)(2)A$1.01997,327ISee footnote(3)
Common Stock168,170D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reporting person purchased 99,010 shares of the Issuer's common stock in a private sale transaction as disclosed in the Share Purchase Agreement dated as of November 15, 2026 at a price of $1.01 per share, which was the last reported sale price of the Issuers common stock on the Nasdaq on November 13, 2026 (the trading day immediately prior to November 15, 2026). The gross proceeds from this private sale transaction were $100,000.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in the transaction set forth in this footnote.
2. On November 19, 2026, the reporting person filed a Form 4 which inadvertently included an incorrect transaction code due to an administrative error. This amendment is being filed to reflect the correct transaction code "A" instead of transaction code "D."
3. The reporting person owns 1,165,497 shares directly and/or indirectly as follows: (i) 168,170 shares of common stock owned by the reporting person, (ii) 150,930 shares in five trusts, each of which has been established for a separate grandchild of the Reporting Person, with each trust owning an aggregate of 30,186 shares of common stock, all trusts with the same terms, over which the Reporting Person has voting and dispositive authority, (iii) 846,397 shares of common stock owned by MFE, LLC over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims pecuniary interest in 20% of MFE, LLC and therefore disclaims 169,279 shares of the 846,397 shares of common stock owned by MFE, LLC, which 169,279 shares are beneficially owned by other members of the limited liability company.
/s/ Anthony Baldor, Attorney-in-fact11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading